open access
Retrospective analysis of the treatment of BRCA1 and BRCA2 mutation carriers – the experience of a single-center tertiary institution
, 2, 13
Affiliations- Department of Oncological Physiotherapy, Medical University of Lodz, Lodz, Poland
- Department of Surgical Oncology and Breast Diseases, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland
- Breast Unit Cancer Center, Copernicus Memorial Hospital, Lodz, Poland
open access
Abstract
Introduction. BRCA1/2 mutation carriers are at a higher risk of developing breast cancer. There are several established risk-reducing therapies. Our study aimed to characterize the BRCA1/2 mutation carriers, and to evaluate the implemented treatment methods.
Material and methods. Retrospective analysis of clinical records of 96 female patients hospitalized from October 2019 to December 2022 in the Breast Cancer Unit in Lodz, Poland.
Results. Out of 85 BRCA1 and 11 BRCA2 mutation carriers, 96.88% received nipple-sparing or skin-sparing, unilateral or bilateral risk-reducing mastectomies. Out of all the patients, 36 developed 38 breast cancers. One patient was diagnosed with breast cancer 2 years after bilateral risk-reducing mastectomy. The most common breast cancer subtype was triple-negative breast cancer (73.68%). The patients could receive surgery, chemotherapy, endocrine therapy, and radiotherapy. 18 patients had neoadjuvant chemotherapy, in 6 of these patients a complete pathological response (ypT0N0) was achieved.
Conclusions. Oncoplastic bilateral risk-reducing mastectomies are effective and safe procedures.
Abstract
Introduction. BRCA1/2 mutation carriers are at a higher risk of developing breast cancer. There are several established risk-reducing therapies. Our study aimed to characterize the BRCA1/2 mutation carriers, and to evaluate the implemented treatment methods.
Material and methods. Retrospective analysis of clinical records of 96 female patients hospitalized from October 2019 to December 2022 in the Breast Cancer Unit in Lodz, Poland.
Results. Out of 85 BRCA1 and 11 BRCA2 mutation carriers, 96.88% received nipple-sparing or skin-sparing, unilateral or bilateral risk-reducing mastectomies. Out of all the patients, 36 developed 38 breast cancers. One patient was diagnosed with breast cancer 2 years after bilateral risk-reducing mastectomy. The most common breast cancer subtype was triple-negative breast cancer (73.68%). The patients could receive surgery, chemotherapy, endocrine therapy, and radiotherapy. 18 patients had neoadjuvant chemotherapy, in 6 of these patients a complete pathological response (ypT0N0) was achieved.
Conclusions. Oncoplastic bilateral risk-reducing mastectomies are effective and safe procedures.
Keywords
BRCA1/2; breast cancer; risk-reducing mastectomy; hereditary breast cancer; breast cancer unit
About this articleTitle
Retrospective analysis of the treatment of BRCA1 and BRCA2 mutation carriers – the experience of a single-center tertiary institution
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Research paper (original)
Published online
2023-08-21
Page views
77
Article views/downloads
41
DOI
Keywords
BRCA1/2
breast cancer
risk-reducing mastectomy
hereditary breast cancer
breast cancer unit
Authors
Grzegorz J. Stępień
Thomas Wow
Agnieszka Kołacińska-Wow
References (30)- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Pujol P, Barberis M, Beer P, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021; 146: 30–47.
- Kamińska M, Ciszewski T, Łopacka-Szatan K, et al. Breast cancer risk factors. Prz Menopauzalny. 2015; 14(3): 196–202.
- Kuchenbaecker KB, Hopper JL, Barnes DR, et al. BRCA1 and BRCA2 Cohort Consortium. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23): 2402–2416.
- Rosen E, Fan S, Pestell R, et al. BRCA1 gene in breast cancer. J Cell Physiol. 2003; 196(1): 19–41.
- Filippini SE, Vega A. Breast cancer genes: beyond BRCA1 and BRCA2. Front Biosci (Landmark Ed). 2013; 18(4): 1358–1372.
- Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014; 132(2): 428–433.
- Heemskerk-Gerritsen BAM, Menke-Pluijmers MBE, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013; 24(8): 2029–2035.
- Domchek SM, Friebel TM, Singer CF, et al. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. JAMA. 2010; 304(9): 967.
- Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. 2012; 118(2): 510–517.
- Wendt C, Margolin S. Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. Acta Oncol. 2019; 58(2): 135–146.
- van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011; 34(2): 71–88.
- Ghoussaini M, Pharoah PDP. Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol. 2009; 5(5): 689–701.
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182): 66–71.
- Yin Li, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1): 61.
- Nowecki Z, Jagiełło-Gruszfeld A, Pogoda K, et al. Leczenie przedoperacyjne chorych na raka piersi i jego wpływ na postępowanie operacyjne oraz radioterapeutyczne (część 2.). Nowotwory. Journal of Oncology. 2021; 71(2): 79–93.
- Galimberti V, Vicini E, Corso G, et al. Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications. Breast. 2017; 34 Suppl 1(Suppl 1): S82–S84.
- Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999; 340(2): 77–84.
- Baildam AD. Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms. Breast. 2019; 46: 48–51.
- Schrag D, Kuntz KM, Garber JE, et al. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997; 336(20): 1465–1471.
- Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019; 177(3): 723–733.
- Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013; 140(1): 135–142.
- K Groth A, Graf R. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the Textured Breast Implant Crisis. Aesthetic Plast Surg. 2020; 44(1): 1–12.
- Jakub JW, Peled AW, Gray RJ, et al. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg. 2018; 153(2): 123–129.
- Baltzer HL, Alonzo-Proulx O, Mainprize JG, et al. MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers. Ann Surg Oncol. 2014; 21(5): 1583–1588.
- Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, et al. HEBON. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015; 136(3): 668–677.
- Liu YL, Breen K, Catchings A, et al. Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncol Pract. 2022; 18(3): 201–209.
- Evans DG, Barwell J, Eccles DM, et al. FH02 Study Group, RGC teams. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014; 16(5): 442.
- Wilson ARM, Marotti L, Bianchi S, et al. EUSOMA (European Society of Breast Cancer Specialists). The requirements of a specialist Breast Centre. Eur J Cancer. 2013; 49(17): 3579–3587.
- Kufel-Grabowska J, Radecka B, Streb J, et al. Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland. Nowotwory. Journal of Oncology. 2020; 70(6): 225–229.